Ward Capoen is Principal at V-Bio Ventures, which he joined in 2016.

Before joining V-Bio, Ward spent over a decade doing molecular biology research at VIB, the John Innes Centre and Harvard Medical School. His expertise spans both plant and animal models, and ranges from fundamental to translational research. 

Prior to V-Bio Ventures, Ward worked as a senior analyst at Candriam Investors Group (formerly Dexia Asset Management), where he was responsible for investment analysis of early-stage listed biotech companies.

Ward holds a PhD in Biotechnology from the University of Gent, Belgium. He also has an MBA from Vlerick Business School, Leuven, Belgium.